Targeting the assembly of Hepatitis B Virus to develop new treatments
Altering Hepatitis B Virus assembly through pharmacological intervention
This study is exploring new treatments for chronic Hepatitis B by using special small molecules to mess up how the virus forms, which could help create non-working virus particles, and it's designed for people looking for better options beyond current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10828310 on NIH RePORTER |
What this research studies
This research focuses on finding new ways to treat chronic Hepatitis B Virus (HBV) infections by disrupting the virus's assembly process. The approach involves using small molecules that can misdirect the formation of the virus's protective capsid, potentially leading to non-functional viral particles. The researchers will combine advanced computer simulations with laboratory experiments to better understand how these compounds interact with the virus and to predict their effectiveness. This innovative strategy aims to overcome the limitations of current therapies that do not provide a cure.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic Hepatitis B Virus infection.
Not a fit: Patients who do not have Hepatitis B Virus infection or those with acute infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new antiviral treatments that effectively eliminate Hepatitis B Virus infections.
How similar studies have performed: Previous research has shown promise in targeting viral capsids for antiviral therapies, indicating potential success for this novel approach.
Where this research is happening
Atlanta, United States
- Georgia Institute of Technology — Atlanta, United States (Active)
Researchers
- Principal investigator: Gumbart, James C. — Georgia Institute of Technology
- Study coordinator: Gumbart, James C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.